抗体的联合治疗的全球市场

抗体的联合治疗的全球市场在2030年前将达到达到3,898亿美元

在COVID-19后改变的商务环境中，2022年1,386亿美元的抗体的联合治疗的全球市场，在2022年～2030年预计将以年复合成长率13.8％的速度成长，在2030年前将达到3,898亿美元。本报告所分析之市场区隔之一的化疗/抗体，年复合成长率将记录9.8％，到分析期间结束时将达到1,527亿美元。考虑疫情后的復苏，抗体/抗体领域今后8年的年复合成长率将修正为18％。

美国市场估算为416亿美元，中国则将以年复合成长率13.3％增长

美国的抗体的联合治疗市场在2022年估算为416亿美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为13.3％，在2030年前将达到679亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以12％和11.7％的速度成长。在欧洲市场中，德国以年复合成长率10％成长。

调查对像企业范例

• Amgen, Inc.
• Biogen, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genmab A/S
• Novartis AG
• Sanofi
• Seattle Genetics, Inc.

目录

第1章 调查手法

第2章 摘要整理

• 市场概要
• 主要企业
• 市场趋势与推动因素
• 全球市场预测

第3章 市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 其他欧洲
• 亚太地区
• 全球其他地区

第4章 竞争

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Combination Antibody Therapy Market to Reach $389.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Combination Antibody Therapy estimated at US$138.6 Billion in the year 2022, is projected to reach a revised size of US$389.8 Billion by 2030, growing at aCAGR of 13.8% over the period 2022-2030. Chemotherapy / Antibody, one of the segments analyzed in the report, is projected to record 9.8% CAGR and reach US$152.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antibody / Antibody segment is readjusted to a revised 18% CAGR for the next 8-year period.

The U.S. Market is Estimated at $41.6 Billion, While China is Forecast to Grow at 13.3% CAGR

The Combination Antibody Therapy market in the U.S. is estimated at US$41.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$67.9 Billion by the year 2030 trailing a CAGR of 13.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12% and 11.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.

Select Competitors (Total 46 Featured) -

• Amgen, Inc.
• Biogen, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genmab A/S
• Novartis AG
• Sanofi
• Seattle Genetics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Combination Antibody Therapy - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Combination Antibody Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 2: World 8-Year Perspective for Combination Antibody Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 4: World 8-Year Perspective for Other Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 6: World 8-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 8: World 8-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 10: World 8-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 12: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 14: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Cancer Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 16: World 8-Year Perspective for Cancer Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 18: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 19: World Combination Antibody Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Chemotherapy / Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 21: World 8-Year Perspective for Chemotherapy / Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Antibody / Antibody by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 23: World 8-Year Perspective for Antibody / Antibody by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 25: USA 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 27: USA 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 29: USA 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 31: Canada 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 33: Canada 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 35: Canada 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• JAPAN
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 37: Japan 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 39: Japan 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 41: Japan 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• CHINA
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 43: China 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 45: China 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 47: China 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• EUROPE
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • TABLE 49: Europe 8-Year Perspective for Combination Antibody Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 51: Europe 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 53: Europe 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 55: Europe 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• FRANCE
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 57: France 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 59: France 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 61: France 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• GERMANY
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 63: Germany 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 65: Germany 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 67: Germany 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 69: Italy 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 71: Italy 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 73: Italy 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• UNITED KINGDOM
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 75: UK 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 77: UK 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 79: UK 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• ASIA-PACIFIC
  • Combination Antibody Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Combination Antibody Therapy by Combination - Chemotherapy / Antibody, Antibody / Antibody and Other Combinations - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 93: Rest of World 8-Year Perspective for Combination Antibody Therapy by Combination - Percentage Breakdown of Value Sales for Chemotherapy / Antibody, Antibody / Antibody and Other Combinations for the Years 2023 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Combination Antibody Therapy by Application - Breast Cancer, Blood Cancer, Lung Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 95: Rest of World 8-Year Perspective for Combination Antibody Therapy by Application - Percentage Breakdown of Value Sales for Breast Cancer, Blood Cancer, Lung Cancer and Other Applications for the Years 2023 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Combination Antibody Therapy by End-Use - Hospitals, Cancer Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • TABLE 97: Rest of World 8-Year Perspective for Combination Antibody Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Institutes and Other End-Uses for the Years 2023 & 2030

IV. COMPETITION